Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
90Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $382.0K | $0.00 | $0.00 |
| 2021 | $0.00 | $-880.9K | $-0.02 |
| 2020 | $0.00 | $-4.37M | $-0.09 |
| 2019 | $0.00 | $-20.14M | $-0.61 |
| 2018 | $102.4K | $-4.31M | $-0.19 |
Social Signal Score
Mentions (2)
- Newsaccessnewswire.com·2d ago·Negative
Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase Potential Fourth-Quarter 2026 Decision Could Mark Entolimod's First National Registration and Open a Pathway to Strategic Stockpiling and Government Procurement Formal review accepted July 22 • Ministry begins technical assessment • Regulatory requirements defined • Potential decision as early as Q4 2026 Near-Term Regulatory Catalyst Formal review underway: Ukraine's Ministry of Health accepted the Entolimod d
View source ↗ - Newsaccessnewswire.com·3d ago·Negative
Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury AFRRI/NIAID Program to Advance Safety and Therapeutic Studies in Rapid Sequence; Top-Line Therapeutic Data Expected in Early Fall Study drug delivered • IACUC approval secured • Safety study planned to start this week Near-Term Program Milestones Study readiness: Entolimod has been delivered to AFRRI, IACUC approval has been obtained, and study animals are being acclimated ahead of dosing.
View source ↗